Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04184050 · ClinicalTrials.gov registry record · Phase 1

Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)

A Phase 1 study of Multiple Myeloma and Multiple Myeloma in Relapse, sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

Active
Registry status
Phase 1
Development phase
100
Enrollment target
12
Study locations

NCT04184050: Active Phase 1 study of Multiple Myeloma and Multiple Myeloma in Relapse, sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

NCT04184050 is a Phase 1 study of Multiple Myeloma and Multiple Myeloma in Relapse that is active but no longer recruiting, run by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 100 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (82% lower). The trial reports 12 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04184050, a Phase 1 study of Multiple Myeloma and Multiple Myeloma in Relapse, is active but no longer recruiting, sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
100 participants
Enrollment target
12
Study locations

Study Summary

Researchers want to learn if MK-4002 (also known as HPN217) can treat relapsed or refractory multiple myeloma (RRMM). The goals of this study are to learn about the safety of different doses of MK-4002 and how well people tolerate them. Researchers also want to learn what happens to different doses of MK-4002 in a person's body over time.

Primary Outcome

An adverse event (AE) is defined as any untoward medical occurrence in a participant administered study drug, which does not necessarily have to have a causal relationship with the study drug. A TEAE is an adverse event that occurs on or after the first dose of study treatment. The number of participants with TEAEs graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (American Society for Transplant and Cellular Therapy \[ASTCT\]

Conditions Studied

Multiple Myeloma Multiple Myeloma in Relapse Multiple Myeloma With Failed Remission Multiple Myeloma of Bone

Interventions

  • DRUG MK-4002

Study Locations (12)

Other

  • Centre Hospitalier Universitaire De Nantes - Nantes
  • Centre Hospitalier Universitaire de Poitiers - Poitiers
  • Josep Carreras Leukaemia Research Institute - Barcelona
  • Hospital Universitario Fundacion Jimenez Diaz (UAM-FJD) - Madrid

Arizona

  • Banner MD Anderson Cancer Center - Gilbert
  • Mayo Clinic Arizona - Phoenix

New York

  • Roswell Park Comprehensive Cancer Center - Buffalo
  • University of Rochester James P Wilmot Cancer Institute - Rochester

California

  • UC San Diego Moores Cancer Center - La Jolla

Kansas

  • The University of Kansas Cancer Center - Fairway

Oregon

  • OHSU - Portland

Washington

  • University of Washington - Seattle Cancer Center Alliance - Seattle

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2020-04-13
Est. Completion 2026-12-31
Phase Phase 1
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

4 total trials

What the registry record for NCT04184050 still lists

NCT04184050 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (82% lower).

The record links to 4 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which MK-4002 is the first listed.

NCT04184050 lists 12 locations in 7 states (Other, Arizona, New York).

Frequently Asked Questions

What is clinical trial NCT04184050 about?

NCT04184050 is a clinical study titled "Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)". Researchers want to learn if MK-4002 (also known as HPN217) can treat relapsed or refractory multiple myeloma (RRMM). The goals of this study are to learn about the safety of different doses of MK-4002 and how well people tolerate them. Researchers also want to learn what happens to different doses ...

What is the current status of trial NCT04184050?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2020-04-13. Estimated completion is 2026-12-31.

What conditions does trial NCT04184050 study?

This clinical trial studies the following conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma With Failed Remission, Multiple Myeloma of Bone.

What interventions are being tested in trial NCT04184050?

The interventions under investigation include: MK-4002 (DRUG).

Who is sponsoring clinical trial NCT04184050?

This trial is sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04184050 being conducted?

This trial has 12 study locations across Arizona, California, Kansas, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04184050's enrollment target sits among peer trials

100 165th of 438 higher than 262 of 438 other Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04184050, the US trial registry maintained by the National Library of Medicine. NCT04184050 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.